CANbridge Pharmaceuticals, Inc., a China-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced...
AiTA Bio, a New York-based bio-MEMS company, today announced it has secured $8.5 million in Series A funding led by Hammerstone Capital, BlackPoint Partners,...
Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), announced dosing of the first participant in the US Phase I study in healthy subjects of its innovative small-molecule...
Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, announced enrollment of the first patient in the Strata Precision...
